About
InduPro, Inc. is a biotechnology company that develops novel therapeutics for cancer and autoimmune diseases by defining and harnessing inherent and induced proximity biology. Their proprietary platforms, Membrane Interactomics (MInt) and Proximity Modalities (ARRIS), utilize AI and machine learning to map cell-surface protein spatial relationships, enabling the discovery of selective co-target pairs for precision drug development.
Key facts
At-a-glance profile data
- Website
- induprotx.com
- Headquarters
- Seattle, United States
- Founded
- 2022
- Total funding
- $77M (Series B)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 12 Aug 2026 | Series B | $77M | The Column Group |
Tech stack
Detected on induprotx.com, last scanned 30 Sept 2026. Run your own scan
- Compliance
- GDPR
- Frontend
- jQuery
- Analytics
- Google Analytics 4
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Microsoft 365
Frequently asked
What does InduPro, Inc. do?
The company's pipeline includes bispecific antibodies, multispecific antibodies, and antibody-drug conjugates.
Is InduPro, Inc. trustworthy and reputable?
StartupHub's Data Trust & Reputation score for InduPro, Inc. is 61 out of 100, based on site security posture and privacy practices.
How much funding has InduPro, Inc. raised?
InduPro, Inc. has raised a total of $77M in funding. The most recent round on record is Series B.